Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia

Blood (2018) 132 (3): 264–276.

https://doi.org/10.1182/blood-2017-12-821363

Published: 2018

Includes: Supplemental data

Journal Articles

Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies

Ondrej Hrusak, MD PhD, Valerie De Haas, MD PhD, Ales Luks, Iveta Janotova, Ester Mejstrikova, MD PhD, Kirsten Bleckmann, MD, Anja Moricke, MD, Julie Irving, PhD, Benigna Konatkowska, Thomas B. Alexander, MD MPH, Hiroto Inaba, MD PhD, Kjeld Schmiegelow, MD DMSc, Simone Stokley, FRCPath,, Jorge Gabriel Rossi, PhD, Maria Sara Felice, MD PhD, Luciano Dalla-Pozza, MB BS FRACP, Jessa Morales, Michael Dworzak, MD, Barbara Buldini, MD, Giuseppe Basso, Myriam Campbell, Maria Elena Cabrera, Neda Marinov, Sarah Elitzur, MD, Shai Izraeli, MD, Drorit Luria, PhD, Tamar Feuerstein, PhD, Alexandra Kolenova, MD PhD, Peter Svec, Elena Kreminska, Karen R. Rabin, MD, Sophia Polychronopoulou, MD PhD, Elaine da Costa, Hanne Vibeke Marquart, MD PhD, Antonis Kattamis, MD, Richard Ratei, Dirk Reinhardt, MD PhD, Anthony V Moorman, PhD, Martin Schrappe, MD, Jan Stary, MD D.Sc.

Blood (2016) 128 (22): 584.

https://doi.org/10.1182/blood.V128.22.584.584

Published: 2016

Journal Articles

T/NK-Cell Immunophenotype with Coexpression of CD56 Predicts Poor Outcome in Childhood T-ALL. Results of the ALL-BFM 2000 Trial

Stephan Fuhrmann, MD, Leonid Karawajew, Richard Schabath, Anja Moricke, MD, Martin Zimmermann, PhD, Wolf-Dieter Ludwig, Martin Schrappe, MD PhD, Richard Ratei

Blood (2016) 128 (22): 760.

https://doi.org/10.1182/blood.V128.22.760.760

Published: 2016

Journal Articles

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

Blood (2016) 127 (17): 2101–2112.

https://doi.org/10.1182/blood-2015-09-670729

Published: 2016

Includes: Supplemental data

Journal Articles

Acute Leukemias of Ambiguous Lineage; Study on 247 Pediatric Patients

Blood (2015) 126 (23): 252.

https://doi.org/10.1182/blood.V126.23.252.252

Published: 2015

Journal Articles

The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5 , CDKN2A , CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1 plus ) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment

Blood (2014) 124 (21): 131.

https://doi.org/10.1182/blood.V124.21.131.131

Published: 2014

Journal Articles

Intermediate-Risk Acute Lymphoblastic Leukemia (ALL) Patients with and without Relapse Differentially Depend on Survival Signals From Microenvironment

Peter Rhein, PhD, Rita Mitlohner, Renate Kirschner-Schwabe, PhD, Christian Hagemeier, MD, PhD, Gunnar Cario, MD, Martin Stanulla, MD, MSc, Martin Schrappe, MD, Iduna Fichtner, PhD, Richard Ratei, MD, Wolf-Dieter Ludwig, Leonid Karawajew, PhD

Blood (2011) 118 (21): 752.

https://doi.org/10.1182/blood.V118.21.752.752

Published: 2011

Journal Articles

High CD45 (PTPRC) Expression Is Associated with An Overall Poor Outcome in Childhood Acute Lymphoblastic Leukemia Treated on the ALL-BFM 2000 Protocol and Exerts An Especially Pronounced Effect in Intermediate Risk Patients

Gunnar Cario, MD, Rita Mitlohner, Martin Zimmermann, PhD, Renja Romey, Peter Rhein, PhD, André Schrauder, MD, Anja Moericke, MD, Jean-Pierre Bourquin, MD, PhD, Wolf-Dieter Ludwig, MD, Richard Ratei, MD, Martin Schrappe, MD, Leonid Karawajew, PhD, Martin Stanulla, MD, MSc

Blood (2011) 118 (21): 742.

https://doi.org/10.1182/blood.V118.21.742.742

Published: 2011

Journal Articles

Conventional Reinduction/Consolidation-Type Therapy Versus Short Course High Intensity Combination Chemotherapy As Post-Induction Treatment for Children with Relapsed Acute Lymphoblastic Leukemia. Early Results of Study ALL-REZ BFM 2002

Arend von Stackelberg, MD, Junko Yamanaka, MD, Gabriele Escherich, MD, Cornelia Eckert, PhD, Richard Ratei, MD, Johann K. Hitzler, MD, Georg Mann, MD, Lucie Sramkova, MD, Jean-Pierre Bourquin, MD, PhD, Martin Schrappe, MD, Günter Henze, MD

Blood (2011) 118 (21): 871.

https://doi.org/10.1182/blood.V118.21.871.871

Published: 2011

Journal Articles

High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation

Nicola Gökbuget, Nadezda Basara, Herrad Baurmann, Joachim Beck, Monika Brüggemann, Helmut Diedrich, Björn Güldenzoph, Gernot Hartung, Heinz-August Horst, Andreas Hüttmann, Guido Kobbe, Ralph Naumann, Richard Ratei, Albrecht Reichle, Hubert Serve, Matthias Stelljes, Andreas Viardot, Mohammed Wattad, Dieter Hoelzer

Blood (2011) 118 (13): 3504–3511.

https://doi.org/10.1182/blood-2011-01-329441

Published: 2011

Journal Articles

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

Blood (2011) 118 (8): 2077–2084.

https://doi.org/10.1182/blood-2011-03-338707

Published: 2011

Includes: Supplemental data

Journal Articles

Prognostic Value of Immunophenotype In Infant ALL – Results of the INTERFANT'99 Study

Blood (2010) 116 (21): 2700.

https://doi.org/10.1182/blood.V116.21.2700.2700

Published: 2010

Journal Articles

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia

Peter Rhein, Rita Mitlohner, Giuseppe Basso, Giuseppe Gaipa, Michael N. Dworzak, Renate Kirschner-Schwabe, Christian Hagemeier, Martin Stanulla, Martin Schrappe, Wolf-Dieter Ludwig, Leonid Karawajew, Richard Ratei

Blood (2010) 115 (18): 3763–3771.

https://doi.org/10.1182/blood-2009-10-247585

Published: 2010

Journal Articles

Time Point-Dependent Concordance of Flow Cytometry and RQ-PCR in the MRD Detection in Childhood ALL: The Experience of the AIEOP-BFM- ALL MRD Study Group

Giuseppe Gaipa, MD, Giovanni Cazzaniga, Renate E Panzer-Grümayer, Marinella Veltroni, Leonid Karawajew, Daniela Silvestri, Barbara Buldini, Richard Ratei, Andre Schrauder, Martin Schrappe, Wolf-Dieter Ludwig, Maria Grazia Valsecchi, Andrea Biondi, Michael N Dworzak, Giuseppe Basso

Blood (2008) 112 (11): 700.

https://doi.org/10.1182/blood.V112.11.700.700

Published: 2008

Journal Articles

Integrin Alpha M Chain Expression at Diagnosis Is Inversely Correlated with Cytoreduction Rate and Is Consistently Up-Regulated during Therapy in Acute Lymphoblastic Leukemia (ALL)

Peter Rhein, Richard Ratei, MD, Rita Mitlohner, Giuseppe Basso, MD, Giuseppe Gaipa, MD, Michael N Dworzak, MD, PhD, Martin Stanulla, MD, Martin Schrappe, MD, Wolf-Dieter Ludwig, MD, Leonid Karawajew, PhD

Blood (2008) 112 (11): 2526.

https://doi.org/10.1182/blood.V112.11.2526.2526

Published: 2008

Journal Articles

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy

Michael N. Dworzak, Angela Schumich, Dieter Printz, Ulrike Pötschger, Zvenyslava Husak, Andishe Attarbaschi, Giuseppe Basso, Giuseppe Gaipa, Richard Ratei, Georg Mann, Helmut Gadner

Blood (2008) 112 (10): 3982–3988.

https://doi.org/10.1182/blood-2008-06-164129

Published: 2008

Journal Articles

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

Blood (2008) 111 (9): 4477–4489.

https://doi.org/10.1182/blood-2007-09-112920

Published: 2008

Includes: Supplemental data

Journal Articles

High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia

Arend von Stackelberg, Reinhard Hartmann, Christoph Bührer, Rüdiger Fengler, Gritta Janka-Schaub, Alfred Reiter, Georg Mann, Kjeld Schmiegelow, Richard Ratei, Thomas Klingebiel, Jörg Ritter, Günter Henze

Blood (2008) 111 (5): 2573–2580.

https://doi.org/10.1182/blood-2007-07-102525

Published: 2008

Journal Articles

Early Evaluation of Bone Marrow Minimal Residual Disease by Flowcytometry on Day 15 Is Feasible on a Multicenter Basis and Bears Strong Prognostic Value in Childhood Acute Lymphoblastic Leukemia. The AIEOP-BFM Experience.

Giuseppe Basso, Giuseppe Gaipa, Maria Grazia Valsecchi, Marinella Veltroni, Michael Dworzak, Richard Ratei, Daniela Silvestri, Alessandra Benetello, Giuseppe Masera, Valentino Conter, Maurizio Arico, Andrea Biondi

Blood (2007) 110 (11): 1423.

https://doi.org/10.1182/blood.V110.11.1423.1423

Published: 2007

Journal Articles

CD11b Is a Therapy-Induced Marker for Monitoring Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.

Peter Rhein, Richard Ratei, M.D., Rita Mitlohner, Martin Schrappe, M.D., Wolf-Dieter Ludwig, M.D., Leonid Karawajew, Ph.D.

Blood (2007) 110 (11): 1424.

https://doi.org/10.1182/blood.V110.11.1424.1424

Published: 2007

NARROW

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia

Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies

T/NK-Cell Immunophenotype with Coexpression of CD56 Predicts Poor Outcome in Childhood T-ALL. Results of the ALL-BFM 2000 Trial

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

Acute Leukemias of Ambiguous Lineage; Study on 247 Pediatric Patients

The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5 , CDKN2A , CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1 plus ) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment

Intermediate-Risk Acute Lymphoblastic Leukemia (ALL) Patients with and without Relapse Differentially Depend on Survival Signals From Microenvironment

High CD45 (PTPRC) Expression Is Associated with An Overall Poor Outcome in Childhood Acute Lymphoblastic Leukemia Treated on the ALL-BFM 2000 Protocol and Exerts An Especially Pronounced Effect in Intermediate Risk Patients

Conventional Reinduction/Consolidation-Type Therapy Versus Short Course High Intensity Combination Chemotherapy As Post-Induction Treatment for Children with Relapsed Acute Lymphoblastic Leukemia. Early Results of Study ALL-REZ BFM 2002

High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

Prognostic Value of Immunophenotype In Infant ALL – Results of the INTERFANT'99 Study

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia

Time Point-Dependent Concordance of Flow Cytometry and RQ-PCR in the MRD Detection in Childhood ALL: The Experience of the AIEOP-BFM- ALL MRD Study Group

Integrin Alpha M Chain Expression at Diagnosis Is Inversely Correlated with Cytoreduction Rate and Is Consistently Up-Regulated during Therapy in Acute Lymphoblastic Leukemia (ALL)

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia

Early Evaluation of Bone Marrow Minimal Residual Disease by Flowcytometry on Day 15 Is Feasible on a Multicenter Basis and Bears Strong Prognostic Value in Childhood Acute Lymphoblastic Leukemia. The AIEOP-BFM Experience.

CD11b Is a Therapy-Induced Marker for Monitoring Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only